3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
3
Cholangiocarcinoma
2
Adenocarcinoma Of Esophagus
2
Sarcoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Cisplatin
15
Gemcitabine
14
durvalumab
9
pembrolizumab
7
Oxaliplatin
6
Bevacizumab
6
Capecitabine
5
lenvatinib
4
S 1 (combination)
3
Liquid Biopsy
3
Irinotecan
3
Folfox protocol
3
Fluorouracil
3
Carboplatin
3
zanidatamab
2
tremelimumab
2
envafolimab
2
Trastuzumab
2
Nivolumab
2
Leucovorin
2
Injections
2
Blood Specimen Collection
2
Albumin-Bound Paclitaxel
2
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
poly ICLC
1
niraparib
1
neratinib
1
larotrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
futibatinib
×
90 days
×
Clear all
NCT05615818
2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3
Recruiting
800 enrolled